Adverum

<!-- Name:DistributionId Value:8837593 --> <!--…
Read More...

<!-- Name:DistributionId Value:8830389 --> <!--…
Read More...

- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead…
Read More...

- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept…
Read More...

REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
Read More...

REDWOOD CITY, Calif., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
Read More...

- Cash runway extended into 2025 due to corporate restructuring to prioritize the clinical development of ADVM-022 and…
Read More...

REDWOOD CITY, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
Read More...

REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage…
Read More...

REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
Read More...